Nisarg J. Shah

Nisarg J. Shah

Auto-generated profile, based on publicly available information

Nisarg J. Shah

Department of Nanoengineering, University of California, San Diego, La Jolla, CA 92093, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2019 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
MLMiguel Angel Lopez‐Ramirez
Miguel Angel Lopez‐Ramirez
Fernando SotoFernando Soto
Fernando Soto
CWChao Wang
Chao Wang
RRRicardo Rueda
Ricardo Rueda
SSSourabh Shukla
Sourabh Shukla
Joseph WangJoseph Wang
Joseph Wang

14 January 2020 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
NSNisarg J. Shah
Nisarg J. Shah
ANAlexander J. Najibi
Alexander J. Najibi
TSTing-Yu Shih
Ting-Yu Shih
AMAngelo S. Mao
Angelo S. Mao
ASAzeem Sharda
Azeem Sharda
DMDavid J. Mooney
David J. Mooney

11 February 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
NSNisarg J. Shah
Nisarg J. Shah
AMAngelo S. Mao
Angelo S. Mao
TSTing-Yu Shih
Ting-Yu Shih
MKMatthew D. Kerr
Matthew D. Kerr
ASAzeem Sharda
Azeem Sharda
DSDavid T. Scadden
David T. Scadden

24 December 2022 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
DMDavid A. McBride
David A. McBride
NDNicholas C. Dorn
Nicholas C. Dorn
MYMina Yao
Mina Yao
WJWade T. Johnson
Wade T. Johnson
WWWei Wang
Wei Wang
NSNisarg J. Shah
Nisarg J. Shah

31 August 2020 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
MKMatthew D. Kerr
Matthew D. Kerr
DMDavid A. McBride
David A. McBride
ACArun K. Chumber
Arun K. Chumber
NSNisarg J. Shah
Nisarg J. Shah
Breakthroughs in cancer immunotherapy have spurred interest in the development of vaccines to mediate prophylactic protection and therapeutic efficacy against primary tumors or to prevent relapse. ...

9 December 2020 in EMJ Innovations
Verified
Journal Article
Open access
DMDavid McBride
David McBride
MKMatthew Kerr
Matthew Kerr
NDNicholas Dorn
Nicholas Dorn
DODora Ogbonna
Dora Ogbonna
ESEvan Santos
Evan Santos
NSNisarg Shah
Nisarg Shah
Inflammation, an essential cytokine-mediated process for generating a neutralising immune response against pathogens, is generally protective. However, aberrant or excessive production of proinflammatory cytokines is associated with uncontrolled local and systemic inflammation, resulting in cell death and often irreversible tissue damage. Uncontrolled inflammation can manifest over timescales spanning hours to years and is primarily dependent on the triggering event. Rapid and potentially lethal increases in cytokine production, or ‘cytokine storm’, develops in hours to days, and is associated with cancer cell-based immunotherapies, such as chimeric antigen receptor T-cell therapy. On the other hand, some bacterial and viral infections with high microbial replication or highly potent antigens elicit immune responses that result in supraphysiological systemic cytokine concentrations, which manifest over days to weeks. Immune dysregulation in autoimmune diseases can lead to chronic cytokine-mediated tissue damage spanning months to years, which often occurs episodically. Upregulation of IL-1, IL-6, IFN-γ, TNF, and granulocyte macrophage colony-stimulating factor frequently coincides with cytokine storm, sepsis, and autoimmune disease. Inhibition of proinflammatory molecules via antagonist monoclonal antibodies has improved clinical outcomes, but the complexity of the underlying immune dysregulation results in high variability. Rather than a ‘one size fits all’ treatment approach, an identification of disease endotypes may permit the development of effective therapeutic strategies that address the contributors of disease progression. Here, the authors present a literature review of the cytokine-associated aetiology of acute and chronic cytokine-mediated tissue damage, describe successes and challenges in developing clinical treatments, and highlight advancements in preclinical therapeutic strategies for mitigating pathological cytokine production.